These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1903726

  • 1. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
    Anttila L, Ding YQ, Ruutiainen K, Erkkola R, Irjala K, Huhtaniemi I.
    Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
    [Abstract] [Full Text] [Related]

  • 2. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.
    Dale PO, Tanbo T, Vaaler S, Abyholm T.
    Fertil Steril; 1992 Sep; 58(3):487-91. PubMed ID: 1521640
    [Abstract] [Full Text] [Related]

  • 3. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L, Koskinen P, Kaihola HL, Erkkola R, Irjala K, Ruutiainen K.
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [Abstract] [Full Text] [Related]

  • 4. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 5. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V, Barash A, Shoham Z, Koistinen R, Seppala M, Hen M, Lunenfeld B, Zadik Z.
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [Abstract] [Full Text] [Related]

  • 6. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
    Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, Kuglin D, Mokrzycka J, Mentel A.
    Endokrynol Pol; 2005 Jan; 56(6):921-6. PubMed ID: 16821212
    [Abstract] [Full Text] [Related]

  • 7. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 9. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A, Rosenn B, Palti Z, Ebstein B, Har-Nir R, Ron M.
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [Abstract] [Full Text] [Related]

  • 10. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A, Mandeli J, Fluhr H, Dobrjansky A.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [Abstract] [Full Text] [Related]

  • 11. Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels.
    Tropeano G, Vuolo IP, Lucisano A, Liberale L, Barini A, Carfagna P, Caroli G, Menini E, dell'Acqua S.
    J Endocrinol Invest; 1996 Mar; 19(3):139-45. PubMed ID: 8743278
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
    Seyam E, Hefzy E.
    Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
    [Abstract] [Full Text] [Related]

  • 13. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [Abstract] [Full Text] [Related]

  • 14. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM, Tiitinen A, Stenman UH, Seppälä M, Laatikainen T.
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [Abstract] [Full Text] [Related]

  • 15. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
    Apter D, Bützow T, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
    [Abstract] [Full Text] [Related]

  • 16. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
    Toscano V, Bianchi P, Balducci R, Guglielmi R, Mangiantini A, Lubrano C, Sciarra F.
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
    [Abstract] [Full Text] [Related]

  • 17. Dexamethasone suppresses sex-hormone binding globulin.
    Blake RE, Rajguru S, Nolan GH, Ahluwalia BS.
    Fertil Steril; 1988 Jan; 49(1):66-70. PubMed ID: 3121398
    [Abstract] [Full Text] [Related]

  • 18. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 19. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 20. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X, Lin JF.
    Zhonghua Yi Xue Za Zhi; 2005 Dec 07; 85(46):3266-71. PubMed ID: 16409817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.